Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

98.68 -0.39 (-0.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
58 59 Next >
Vaccine Makers Mull Price Increase For COVID-19 Boosters Amid Falling Demand
Via Benzinga
Boston University's COVID-19 Created In Lab Research Comes Under Scrutiny
Boston University created an artificial form of COVID-19 in a laboratory. Now, U.S. health officials have launched an inquiry into a controversial study. The Boston University research was designed to... 
Via Benzinga
Why Moderna Stock Dropped Today
Competition is intensifying. 
Via The Motley Fool
Why Novavax Stock Couldn't Win on Wednesday
FDA authorization isn't necessarily a slam dunk for a company. 
Via The Motley Fool
European Advisory Committee Backs Pfizer/BioNTech's COVID Shot For Younger Kids
Via Benzinga
Pfizer's Partner BioNTech Signs Research Pact With Australia
Via Benzinga
Why BioNTech SE And Novavax Shares Are Diving
BioNTech SE - ADR (NASDAQ: BNTX) and Novavax, Inc. (NASDAQ: NVAX) shares are trading lower by 4.07% to $133.28 and 7.68% to $18.76, respectively, ahead of the close of Tuesday's session. Vaccine stock 
Via Benzinga
3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off
All three of these medical stocks offer a high-yield dividend. 
Via The Motley Fool
Bulls And Bears Of The Week: Amazon, Tesla, Apple, Meta And Why An Analyst Is Turning Less Positive On 2 Legacy Automakers
Benzinga examined the prospects for many investors' favorite stocks over the past week — here's a look at some of our top stories. 
Via Benzinga
Why Novavax Stock Had an Ugly Friday
Investors ding the biotech's shares one day after it reported quite good news about an experimental vaccine. 
Via The Motley Fool
Pfizer/BioNTech's Updated Omicron Adapted COVID-19 Shot Increases Neutralizing Antibodies Above Pre-Booster Levels
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ:  
Via Benzinga
These 2 Stocks Gave Investors a Nice Surprise Wednesday
Markets moved slightly lower in advance of the latest data on inflation. 
Via The Motley Fool
Why Pfizer Partner BioNTech SE Shares Are Trading Higher
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 5.37% to $136.45 going into the close of Wednesday's trading session after the FDA granted Emergency Use Authorization to the company's... 
Via Benzinga
FDA Authorizes Pfizer/BioNtech's Updated COVID-19 Booster Shots For Kids 5-11 Years
Via Benzinga
Moderna, BioNTech And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mostly higher, with the Dow Jones gaining more than 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Dear NVAX Stock Fans, Mark Your Calendars for Oct. 11
Shares of NVAX stock are climbing ahead of the World Vaccine Congress Europe 2022, where Novavax will share new vaccine data. 
Via InvestorPlace
Pfizer's Executive Says European COVID-19 Vaccine Contract Negotiations Did Not Happen Over Text Message
A Pfizer Inc (NYSE: PFE) executive has "categorically" ruled out that the pharma giant's chief executive agreed on the European COVID-19 contract via mobile phone text messages. 
Via Benzinga
7 Blue-Chip Stocks That Are Too Cheap to Ignore
It's time to pounce on the opportunity to buy high-quality at bargain prices, with these seven cheap blue-chip stocks. 
Via InvestorPlace
3 Dirt-Cheap Stocks That Could Soar 48% to 68%, According to Wall Street
These stocks could attract both value and growth investors. 
Via The Motley Fool
Top Five Weekend Stock Stories - Sunday, Oct. 2nd
Catch up on the weekend's top five stories with this must read list. 
Via Talk Markets
As Moderna Grapples With Supply Shortage, FDA Gives Nod To Additional Lots of COVID-19 Booster
Via Benzinga
7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic’s Over’
Investors have seven widely-followed vaccine stocks to sell now, after the world decided the pandemic is over. 
Via InvestorPlace
iPhone 14 Popular In China?, Netflix May Lose Comics, Elon Musk's Starlink Slows, Byron Allen Faces $10B Lawsuit And More Top Financial Media Stories Monday, Sept. 26
Bloomberg 
Via Benzinga
Pfizer/BioNTech Seek FDA Emergency Nod For Updated COVID-19 Shot For Kids Under 11 Years
Via Benzinga
Pfizer CEO Contracts COVID-19 Infection For Second Time
Pfizer Inc's (NYSE: PFE) CEO Albert Bourla said he had tested positive for COVID-19. 
Via Benzinga
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Kids, But Scrambles Supply Challenges
Last week, Moderna Inc (NASDAQ: MRNA) said it asked the FDA to authorize the use of its updated booster shot in children ages 6 to 17. The company expects to complete a request for the use of the... 
Via Benzinga
Switzerland To Dispose 10M Expired COVID-19 Vaccine Doses From Moderna
Via Benzinga
Why Is Novavax (NVAX) Stock Falling Today?
Novavax still has cash, but it needs to get approval for another vaccine if NVAX stock is to be worth buying again. 
Via InvestorPlace
Nikola, Super Micro Computer And Other Big Losers From Monday
U.S. stocks closed higher with the Dow Jones gaining around 197 points on Monday. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Check Out What Whales Are Doing With BNTX
Someone with a lot of money to spend has taken a bullish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.